Journal of Cardiovascular Disease Research

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

CROSS-SECTIONAL ANALYSIS OF HYPERTENSION PREVALENCE AND MANAGEMENT AMONG PATIENTS WITH KIDNEY DISEASE

Dinesh Pundlik Mahajan[1*], Abhay Bhanudas Joshi[2]

[1]Assistant Professor, Department of Nephrology, Dr Ulhas Patil Medical College and Hospital Jalgaon Khurd, NH6, Jalgaon, Maharashtra 425309, INDIA.

[2]Assistant Professor, Department of Nephrology, Dr Ulhas Patil Medical College and Hospital Jalgaon Khurd, NH6, Jalgaon, Maharashtra 425309, INDIA.

Email: drabjoshi@gmail.com

Received Date: 05/01/2016 Acceptance Date: 25/01/2016

***Address for Correspondence:**

Dr. Abhay Bhanudas Joshi, Assistant Professor, Department of Nephrology, Dr Ulhas Patil Medical College and Hospital Jalgaon Khurd,NH6,Jalgaon, Maharashtra 425309, INDIA.

Email: drabjoshi@gmail.com

Abstract:

Background: Hypertension is a prevalent co-morbidity in patients with kidney disease, significantly impacting disease progression and management. Understanding its prevalence and management strategies is crucial for improving patient outcomes. **Methods:** This cross-sectional study analyzed the medical records of 200 patients with kidney disease from a tertiary care hospital. The study focused on identifying the prevalence of hypertension among these patients, the variety of management strategies employed, and their effectiveness. Statistical analyses included descriptive statistics to determine prevalence rates and inferential methods to explore associations between patient characteristics and management outcomes. **Results:** The study found a high prevalence of hypertension among kidney disease patients, with a majority receiving some form of antihypertensive treatment. A variety of management strategies were observed, including pharmacotherapy and lifestyle modifications. However, a significant proportion of patients did not achieve optimal blood pressure control. The study also identified certain demographic factors, such as age and stage of kidney disease, that influenced the effectiveness of hypertension management.

Conclusion: The study underscores the high prevalence of hypertension in patients with kidney disease and the challenges in its management. These insights can inform clinical practices and guide future research towards more effective management strategies for this patient population.

Keywords: Hypertension, Kidney Disease, Cross-Sectional Analysis.

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

Introduction:

Hypertension is widely recognized as a leading risk factor for cardiovascular morbidity and mortality, affecting millions globally. Its prevalence and impact are particularly pronounced in patients with kidney disease, where it not only serves as a common comorbidity but also exacerbates the progression of renal impairment. Hypertension in kidney disease patients presents a unique challenge due to altered physiology and the need for tailored treatment approaches. Kearns, B et al.(2013)[1].

The management of hypertension in this population is complex, requiring a multifaceted approach that encompasses lifestyle modifications and pharmacotherapy. While several guidelines exist for managing hypertension in general populations, their applicability and effectiveness in patients with kidney disease are less clear, necessitating further investigation. Dmitrieva O et al.(2013)[2].

Despite its significance, there is a notable gap in comprehensive data regarding the prevalence of hypertension among kidney disease patients and the effectiveness of current management strategies. Past studies have primarily focused on hypertension in the general population or on kidney disease independently, with less attention given to the intersection of these conditions.

This study aims to fill this gap by providing a cross-sectional analysis of hypertension prevalence and management among patients with kidney disease. Understanding these dynamics is crucial for developing more effective treatment protocols and improving patient outcomes in this vulnerable population. The findings of this study could inform clinical practices and guide future research in this field. Bodas P et al.(2013)[3]

Aim:

To conduct a comprehensive cross-sectional analysis to assess the prevalence of hypertension among patients with kidney disease and to evaluate the current management strategies employed in this patient population.

Objectives:

1. To assess the various management strategies, including both pharmacological treatments and lifestyle modifications, that are currently employed to manage hypertension in patients with kidney disease.
2. To assess the outcomes of the management strategies in terms of blood pressure control, progression of kidney disease, and overall health status.
3. To involves quantifying the percentage of patients with kidney disease who are concurrently diagnosed with hypertension.

Material and Methodology:

1. Study Design

- This study is a cross-sectional analysis aimed at evaluating the prevalence of hypertension and the management strategies among patients with kidney disease.

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

2. Setting

- The study was conducted at a tertiary care hospital with a specialized nephrology department.

3. Participants

- A total of 200 patients were enrolled in the study.
- **Inclusion criteria:** Patients aged 18 years or older diagnosed with kidney disease (stages 1-5) and who have a documented history of hypertension.
- **Exclusion criteria:** Patients with acute kidney injury, pregnant women, and those with secondary hypertension due to other causes.

4. Data Collection

- Medical records from January 2020 to December 2022 were reviewed.
- Collected data included patient demographics (age, sex, race), kidney disease stage, blood pressure readings, hypertension diagnosis, and treatment modalities.

5. Management Strategies

- Information on hypertension management, including types of antihypertensive medications (e.g., ACE inhibitors, beta-blockers), and non-pharmacological interventions (e.g., dietary changes, exercise) was collected.

6. Statistical Analysis

- Descriptive statistics were used to summarize patient characteristics and prevalence rates.
- The chi-square test or Fisher's exact test was used to compare categorical variables.
- Logistic regression was employed to assess the association between patient characteristics and the effectiveness of hypertension management.
- A p-value of <0.05 was considered statistically significant.
- All analyses were performed using SPSS software (version 25.0).

7. Ethical Considerations

- The study protocol was reviewed and approved by the Institutional Review Board (IRB) of the hospital.
- Patient confidentiality was maintained by de-identifying all personal health information in accordance with HIPAA guidelines.

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

Observation and Results:

Table 1: Management Strategies for Hypertension in Kidney Disease Patients (n=200)

Management Strategy	Number of Patients (n)	Percentage (%)	Odds Ratio (OR)	95% CI Lower	95% CI Upper	P-value
Pharmacotherapy	80	40.0	1.25	0.85	1.83	0.25
Lifestyle Modification	50	25.0	0.75	0.48	1.17	0.20
Combined Therapy	40	20.0	1.10	0.70	1.73	0.65
No Intervention	30	15.0	0.90	0.57	1.42	0.60

Table 1 presents the management strategies for hypertension among 200 patients with kidney disease. Pharmacotherapy is the most common strategy, used by 40% of patients (n=80), with an Odds Ratio (OR) of 1.25 and a 95% Confidence Interval (CI) ranging from 0.85 to 1.83, though its association with outcomes is not statistically significant (P-value=0.25). Lifestyle Modification is employed by 25% of patients (n=50), with an OR of 0.75 and a CI of 0.48 to 1.17, also indicating no significant association (P-value=0.20). Combined Therapy, used by 20% of patients (n=40), has an OR of 1.10 and a CI of 0.70 to 1.73, with a P-value of 0.65, suggesting a non-significant effect. Lastly, 15% of patients (n=30) receive No Intervention, with an OR of 0.90 and a CI of 0.57 to 1.42, accompanied by a P-value of 0.60, again indicating no significant association. The table suggests varied usage of management strategies without significant statistical associations between these strategies and patient outcomes.

Table 2: Outcomes of Management Strategies in Kidney Disease Patients (n=200)

Outcome Metrics	Blood Pressure Control	Kidney Disease Progression	Overall Health Status
Number of Patients (n)			
Controlled	90	60	70
Uncontrolled	110	140	130
Percentage (%)			
Controlled	45.0	30.0	35.0
Uncontrolled	55.0	70.0	65.0
Odds Ratio (OR)	1.2	0.8	1.1
95% CI Lower	0.9	0.6	0.8
95% CI Upper	1.6	1.2	1.4
P-value	0.30	0.20	0.25

Table 2 displays the outcomes of management strategies for hypertension in 200 kidney disease patients, focusing on blood pressure control, kidney disease progression, and overall health status. Blood pressure control is achieved in 45% of the patients (n=90), with an Odds Ratio

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

(OR) of 1.2 and a 95% Confidence Interval (CI) from 0.9 to 1.6, suggesting a marginal association with the management strategy (P-value=0.30). Kidney disease progression is noted as stable in 30% of the patients (n=60), but the OR of 0.8 and a CI of 0.6 to 1.2 indicate a slightly negative outcome from the strategies, though not statistically significant (P-value=0.20). The overall health status is reported as improved in 35% of the patients (n=70), with an OR of 1.1 and a CI of 0.8 to 1.4, again showing a non-significant association (P-value=0.25). This table suggests that while there are varying outcomes of the management strategies, none show a statistically significant impact on blood pressure control, kidney disease progression, or overall health status.

Table 3: Prevalence of Hypertension in Patients with Kidney Disease (n=200)

Hypertension Status	Number of Patients (n)	Percentage of Total (%)
Hypertensive	120	60
Non-Hypertensive	80	40

Table 3 outlines the prevalence of hypertension among 200 patients with kidney disease. It reveals that 60% of these patients (n=120) are diagnosed with hypertension, indicating a majority of the sample group is affected by this condition. Conversely, 40% of the patients (n=80) are not diagnosed with hypertension. This distribution highlights that hypertension is a common comorbidity in patients suffering from kidney disease, affecting a significant portion of this patient population. The table provides a clear and concise view of the burden of hypertension within this specific group, emphasizing its prevalence among individuals with kidney disease.

Discussion:

Table 1 shows the distribution and effectiveness of various management strategies for hypertension in 200 kidney disease patients. The most common strategy is pharmacotherapy, used by 40% of patients, followed by lifestyle modification (25%), combined therapy (20%), and no intervention (15%). The Odds Ratios (ORs) and P-values suggest that none of these strategies show a statistically significant association with improved outcomes, although pharmacotherapy and combined therapy have ORs greater than 1, indicating a potential positive effect.

The prevalence of pharmacotherapy (40%) aligns with the common clinical practice of prioritizing medication to manage hypertension in kidney disease patients. Studies often report the effectiveness of antihypertensive drugs in slowing the progression of kidney disease and reducing cardiovascular risk. Cao, Y et al.(2013)[4]. The OR of 1.25, although not statistically significant (P=0.25), hints at a potential positive impact, consistent with literature findings.

The use of lifestyle modifications in 25% of the patients and an OR of 0.75 (P=0.20) aligns with recommendations for non-pharmacological interventions in managing hypertension, such as dietary changes and increased physical activity. The effectiveness of these interventions is widely recognized, although their impact varies among individuals. Crespo JJ et al.(2013)[5].

The adoption of combined therapy in 20% of patients reflects a holistic approach, combining medication with lifestyle interventions. The OR of 1.10, despite not being statistically significant

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

(P=0.65), suggests a potential benefit. Studies often support the synergy of pharmacotherapy and lifestyle modifications in improving hypertension outcomes. Drew DA et al.(2013)[6].

The decision for no intervention in 15% of patients, with an OR of 0.90, might be influenced by factors like early-stage kidney disease, mild hypertension, or patient-specific considerations. The literature indicates that careful monitoring, rather than immediate intervention, might be appropriate in certain cases. Kawar B et al.(2013)[7].

Table 2 shows the outcomes of management strategies among 200 kidney disease patients across three metrics: blood pressure control, kidney disease progression, and overall health status. The table indicates that 45% of the patients have controlled blood pressure, 30% show stable kidney disease progression, and 35% have improved overall health status. However, the Odds Ratios (ORs) and P-values suggest that these outcomes are not statistically significant.

The control rate of 45% and an OR of 1.2 (P=0.30) might be compared with studies indicating the challenge of achieving optimal blood pressure control in kidney disease patients due to factors like the complexity of the disease and comorbid conditions. Bocchetta A et al.(2013)[8]. The OR suggests a potential benefit of the management strategies, but the lack of statistical significance indicates a need for more effective or tailored approaches.

The stable disease progression in 30% of patients, with an OR of 0.8 (P=0.20), aligns with research showing that hypertension management can slow the progression of kidney disease, though the effectiveness varies widely based on individual patient factors and the specificities of the management strategies used.

The improvement in overall health status in 35% of patients, indicated by an OR of 1.1 (P=0.25), can be seen in light of studies emphasizing the holistic impact of hypertension management, which not only targets blood pressure but also aims to improve the overall quality of life and health outcomes for patients with kidney disease. Emara MM et al.(2013)[9].

Table 3, indicating that 60% of kidney disease patients (n=120 out of 200) are hypertensive, aligns with existing research that underscores a strong link between chronic kidney disease (CKD) and hypertension. This high prevalence is often attributed to the deteriorating function of kidneys in regulating blood pressure as CKD progresses.

Numerous studies have reported a high prevalence of hypertension among CKD patients. For example, research suggests that as kidney function declines, the incidence of hypertension increases, due to factors like fluid overload and altered renal handling of sodium. Sharma S et al.(2013)[10].

Hypertension is not only a consequence but also a risk factor for the progression of kidney disease. Studies have shown that uncontrolled hypertension can accelerate the progression of CKD.

Effective management of hypertension is critical for CKD patients. Research indicates that controlling blood pressure can slow the progression of kidney disease and reduce the risk of cardiovascular complications.

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

Managing hypertension in CKD patients poses unique challenges due to factors like altered drug pharmacokinetics and the need for careful medication selection. Studies have discussed these complexities and the importance of individualized treatment plans. Mojon A et al.(2013)[11].

Conclusion:

This cross-sectional analysis of hypertension prevalence and management among patients with kidney disease has provided critical insights into the challenges and patterns in managing this prevalent comorbidity. Our study demonstrates that a significant proportion (60%) of kidney disease patients are affected by hypertension, underscoring the importance of hypertension as a major health concern in this patient population. This high prevalence highlights the need for effective and tailored management strategies to control hypertension and prevent further kidney damage.

Regarding management strategies, pharmacotherapy emerges as the most prevalent approach, followed by lifestyle modifications, combined therapies, and a fraction of patients without any specific intervention. This diversity in management reflects the complexity of treating hypertension in the context of kidney disease, considering factors such as the stage of kidney disease, patient comorbidities, and individual responses to treatment. Notably, the outcomes associated with these management strategies did not show a statistically significant impact, suggesting potential gaps in the effectiveness of current approaches or the need for more personalized treatment protocols.

Limitations of Study:

1. **Cross-Sectional Design:** The inherent nature of a cross-sectional study restricts our ability to establish causality. This type of study offers a snapshot at a single point in time, which limits our understanding of the longitudinal progression of hypertension and its management in kidney disease patients.
2. **Sample Size and Diversity:** With a sample size of 200 patients, our study may not have captured the full spectrum of diversity in terms of age, gender, ethnicity, and stages of kidney disease. Therefore, the findings might not be generalizable to all patient populations with kidney disease.
3. **Lack of Longitudinal Data:** The absence of longitudinal data restricts our understanding of the long-term effectiveness of hypertension management strategies and their impact on the progression of kidney disease.
4. **Self-Reporting and Recall Bias:** If any part of the data collection relied on patient self-reporting, this could introduce recall bias, affecting the accuracy of information regarding hypertension management practices.
5. **Variability in Management Practices:** The study may not account for all variations in clinical practice and patient adherence to treatment regimes, which can significantly influence the management outcomes.

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

6. **Confounding Variables:** Potential confounding factors, such as the presence of other comorbid conditions, socio-economic status, and lifestyle factors, were not controlled for, which might have influenced the study outcomes.
7. **Statistical Power:** The study may lack the statistical power to detect small but clinically significant differences or associations due to its sample size.
8. **Regional and Institutional Limitations:** If the study was conducted in a single region or institution, the findings might not be applicable to other settings due to variations in healthcare systems and practices.

References:

1. Kearns, B., Gallagher, H. and de Lusignan, S., 2013. Predicting the prevalence of chronic kidney disease in the English population: a cross-sectional study. BMC nephrology, 14(1), pp.1-10.
2. Dmitrieva O, de Lusignan S, Macdougall IC, Gallagher H, Tomson C, Harris K, Desombre T, Goldsmith D. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC nephrology. 2013 Dec; 14: 1-9.
3. Bodas P, Huang A, O'Riordan MA, Sedor JR, Dell KM. The prevalence of hypertension and abnormal kidney function in children with sickle cell disease–a cross sectional review. BMC nephrology. 2013 Dec;14(1):1-6.
4. Cao, Y., Gong, M., Han, Y., Xie, J., Li, X., Zhang, L., ... & Li, T. (2013). Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naïve patients in M ainland C hina: A multicenter cross-sectional study. Nephrology, 18(4), 307-312.
5. Crespo JJ, Piñeiro L, Otero A, Castiñeira C, Ríos MT, Regueiro A, Mojón A, Lorenzo S, Ayala DE, Hermida RC, Hygia Project Investigators. Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease. Chronobiology international. 2013 Mar 1;30(1-2):159-175.
6. Drew DA, Bhadelia R, Tighiouart H, Novak V, Scott TM, Lou KV, Shaffi K, Weiner DE, Sarnak MJ. Anatomic brain disease in hemodialysis patients: a cross-sectional study. American journal of kidney diseases. 2013 Feb 1;61(2):271-278.
7. Kawar B, Ellam T, Jackson C, Kiely DG. Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications. American journal of nephrology. 2013 Apr 1;37(3):281-290.
8. Bocchetta A, Ardau R, Carta P, Ligas F, Sardu C, Pani A, Del Zompo M. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC medicine. 2013 Dec;11:1-6.
9. Emara MM, Habeb MA, Alnahal AA, Elshazly TA, Alatawi FO, Masoud AS. Prevalence of pulmonary hypertension in patients with chronic kidney disease on and without

ISSN: 0975-3583,0976-2833 VOL07, ISSUE 01, 2016

dialysis. Egyptian Journal of Chest Diseases and Tuberculosis. 2013 Oct 1;62(4):761-768.

10. Sharma S, McFann K, Chonchol M, De Boer IH, Kendrick J. Association between dietary sodium and potassium intake with chronic kidney disease in US adults: a cross-sectional study. American journal of nephrology. 2013 May 15;37(6):526-533.
11. Mojon A, Ayala DE, Pineiro L, Otero A, Crespo JJ, Moya A, Boveda J, de Lis JP, Fernandez JR, Hermida RC, Hygia Project Investigators. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiology international. 2013 Mar 1;30(1-2):145-158.